• KOL
    • Venous Thromboembolism
    • Pauline Wimberger
    • Pauline Wimberger: Influence Statistics

      Pauline Wimberger

      Pauline Wimberger

      National Center for Tumor Diseases (NCT/UCC), Dresden, Germany | for the ATTAIN Investigators | Department of Gynecology and Obstetrics, Technische Universität Dresden, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Pauline Wimberger:Expert Impact

      Concepts for whichPauline Wimbergerhas direct influence:Venous thromboembolism,Elective surgery,Patients surgery,Sars cov2 patients,Patients sars cov2,Sars‐cov‐2 infection,Ovarian cancer,Pulmonary complications.

      Pauline Wimberger:KOL impact

      Concepts related to the work of other authors for whichfor which Pauline Wimberger has influence:Ovarian cancer,Elective surgery,Antiplatelet agents,Angiogenesis inhibitors,Venous thromboembolism,Sars‐cov‐2 infection,Pulmonary complications.

      KOL Resume for Pauline Wimberger

      Year
      2022

      National Center for Tumor Diseases (NCT/UCC), Dresden, Germany

      for the ATTAIN Investigators

      2021

      National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.

      2020

      Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany

      Sample of concepts for which Pauline Wimberger is among the top experts in the world.
      Concept World rank
      sorafenib topotecan #51
      topotecan platinum #59
      nct02338167 #69
      praegnant #90

      Prominent publications by Pauline Wimberger

      KOL-Index: 11583

      Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome ...

      Known for Surgery Patients | Sars‐cov‐2 Infection | Child Child | International Prospective | Operative Sars
      KOL-Index: 9613

      BACKGROUND: Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer.

      METHODS: We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously ...

      Known for Ovarian Cancer | Progressionfree Survival | Maintenance Therapy | Topotecan Platinum | Patients Progression
      KOL-Index: 5083

      SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients ...

      Known for Sars‐cov‐2 Infection | Venous Thromboembolism | Surgery Sars | Risk Postoperative | Cohort Patients
      KOL-Index: 5076

      We aimed to determine the impact of pre-operative isolation on postoperative pulmonary complications after elective surgery during the global SARS-CoV-2 pandemic. We performed an international prospective cohort study including patients undergoing elective surgery in October 2020. Isolation was defined as the period before surgery during which patients did not leave their house or receive visitors from outside their household. The primary outcome was postoperative pulmonary ...

      Known for Elective Surgery | Pre‐operative Isolation | Sarscov2 Infection | International Prospective | Cov2 Pandemic
      KOL-Index: 3373

      OBJECTIVE: DCVAC/OvCa is an active cellular immunotherapy designed to stimulate an immune response against ovarian cancer. We explored the safety and efficacy of DCVAC/OvCa plus carboplatin and gemcitabine in platinum-sensitive ovarian cancer.

      METHODS: In this open-label, parallel-group, phase 2 trial (ClinicalTrials.gov number NCT02107950), patients with platinum-sensitive ovarian cancer relapsing after first-line chemotherapy were randomized to DCVAC/OvCa and chemotherapy or ...

      Known for Ovarian Cancer | Dendritic Cell | Based Immunotherapy | Progressionfree Survival | Chemotherapy Patients
      KOL-Index: 3003

      A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics ...

      Known for Endometrial Carcinoma | European Society | Gynaecological Oncology | Neoplasms Europe | Consensus Development
      KOL-Index: 2297

      PURPOSE: Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome.

      PATIENTS AND METHODS: Germline DNA ...

      Known for Brca1 Genes | Metastatic Breast | Cancer Mbc | Neoplasms Female | Mutation Status
      KOL-Index: 1129

      Purpose Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced breast cancer. While pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard therapy options seem to be exhausted up to now after the treatment of patients with these two therapy options. Therefore, it is important to have data that describes the therapy situation and prognosis after T-DM1 treatment. Methods The PRAEGNANT metastatic breast ...

      Known for Treatment Landscape | Patient Characteristics | Advanced Breast | Therapy Setting
      KOL-Index: 819

      PURPOSE: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC).

      PATIENTS AND METHODS: Female patients with advanced TNBC, with high levels of tumor-associated macrophages not amenable to curative treatment by surgery or radiotherapy were enrolled. Lacnotuzumab was dosed at 10 mg/kg every 3 weeks, ± a dose on cycle 1, day 8. Gemcitabine (1,000 mg/m2) and carboplatin (dose ...

      Known for Triple Negative | Tumorassociated Macrophages | Cancer Tnbc | Factor 1 | Colony Stimulating
      KOL-Index: 651

      BACKGROUND: In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a setting reflecting clinical practice.

      METHODS: This open-label, single-arm trial of olaparib (300 mg, ...

      Known for Metastatic Breast | Cancer Mbc | Her2 Negative | Received Dose | Single Arm
      KOL-Index: 445

      BACKGROUND: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time.

      METHODS: From 2017 to 2020 we conducted a prospective ...

      Known for 2017 2020 | Study Adds

      Key People For Venous Thromboembolism

      Top KOLs in the world
      #1
      John A Heit
      venous thromboembolism pulmonary embolism alcohol dependence
      #2
      Harry Roger Büller
      pulmonary embolism venous thrombosis major bleeding
      #3
      Paolo Prandoni
      venous thromboembolism pulmonary embolism vein thrombosis
      #4
      Samuel Zachary Goldhaber
      pulmonary embolism atrial fibrillation major bleeding
      #5
      Martin Hendrik Prins
      venous thromboembolism pulmonary embolism intermittent claudication
      #6
      Giancarlo Agnelli
      venous thromboembolism pulmonary embolism atrial fibrillation

      National Center for Tumor Diseases (NCT/UCC), Dresden, Germany | for the ATTAIN Investigators | Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany | Helmholtz-Zentrum Dresden–Rossendorf (HZDR), Dresden, Germany

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.